Search research articles
Contact Us
Filters
Showing results (51-60 of 54) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 54 results.
American Journal of Respiratory and Critical Care Medicine
|
July 3, 2026
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
Daichi Fujimoto, Mitsuhiro Abe, Kenta Murotani, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2025
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
Shigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology
|
March 17, 2025
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study
Fumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, et al.
JTO Clinical and Research Reports
|
December 4, 2023
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
Yasunori Murata, Shigeru Tanzawa, Toshihiro Misumi, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 54) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 54 results.
American Journal of Respiratory and Critical Care Medicine
|
July 3, 2026
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
Daichi Fujimoto, Mitsuhiro Abe, Kenta Murotani, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2025
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
Shigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology
|
March 17, 2025
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study
Fumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, et al.
JTO Clinical and Research Reports
|
December 4, 2023
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
Yasunori Murata, Shigeru Tanzawa, Toshihiro Misumi, et al.
Page
of 6